Management of Inflammatory Bowel Disease: Does Rifaximin Offer Any Promise?

Publisher： Karger

E-ISSN： 1421-9794|51|1|96-102

ISSN： 0009-3157

Source： Chemotherapy, Vol.51, Iss.1, 2005-04, pp. : 96-102

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pancreatic Cancer: Does Octreotide Offer Any Promise?

By  

Chemotherapy, Vol. 47, Iss. 2, 2001-03 ,pp. : 134-149

Karger

Access to resources Recommend Favorite

Management of Diverticular Disease: Is There Room for Rifaximin?

By  

Chemotherapy, Vol. 51, Iss. 1, 2005-04 ,pp. : 110-114

Karger

Access to resources Recommend Favorite

Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease

By Nielsen Ole Haagen   Soendergaard Christoffer   Vikner Malene Elbaek   Weiss Günter  

Nutrients, Vol. 10, Iss. 1, 2018-01 ,pp. : 82-82

MDPI

Access to resources Recommend Favorite

Flavonoids in Inflammatory Bowel Disease: A Review

By Vezza Teresa   Rodríguez-Nogales Alba   Algieri Francesca   Utrilla Maria Pilar   Rodriguez-Cabezas Maria Elena   Galvez Julio  

Nutrients, Vol. 8, Iss. 4, 2016-04 ,pp. : 211-211

MDPI

Access to resources Recommend Favorite

Effects of Non-Starch Polysaccharides on Inflammatory Bowel Disease

By Nie Ying   Lin Qinlu   Luo Feijun  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-06 ,pp. : 1372-1372

MDPI

Access to resources Recommend Favorite